Charles Schwab
COGT icon

Charles Schwab’s Cogent Biosciences COGT Stock Holding History

Charles Schwab’s Portfolio COGT Stock Details COGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$56.1M Buy
1,449,300
+206,978
+17% +$7.24M 0.01% 1169
2026
Q1 		$47.8M Sell
1,242,322
-38,457
-3% -$1.42M 0.01% 1183
2025
Q4 		$45.5M Buy
1,280,779
+90,134
+8% +$2.53M 0.01% 1221
2025
Q3 		$17.1M Buy
1,190,645
+303,658
+34% +$3.6M ﹤0.01% 1837
2025
Q2 		$6.37M Buy
886,987
+60,692
+7% +$336K ﹤0.01% 2228
2025
Q1 		$4.95M Sell
826,295
-6,860
-0.8% -$53.8K ﹤0.01% 2275
2024
Q4 		$6.5M Buy
833,155
+7,362
+0.9% +$73.4K ﹤0.01% 2214
2024
Q3 		$8.92M Buy
825,793
+139,096
+20% +$1.35M ﹤0.01% 2079
2024
Q2 		$5.79M Buy
686,697
+67,661
+11% +$513K ﹤0.01% 2295
2024
Q1 		$4.16M Buy
619,036
+13,007
+2% +$80.4K ﹤0.01% 2349
2023
Q4 		$3.56M Buy
606,029
+13,537
+2% +$104K ﹤0.01% 2452
2023
Q3 		$5.78M Buy
592,492
+397,765
+204% +$4.72M ﹤0.01% 2188
2023
Q2 		$2.31M Buy
194,727
+19,294
+11% +$221K ﹤0.01% 2505
2023
Q1 		$1.89M Buy
175,433
+4,128
+2% +$52.8K ﹤0.01% 2541
2022
Q4 		$1.98M Buy
171,305
+2,926
+2% +$36.3K ﹤0.01% 2574
2022
Q3 		$2.51M Buy
168,379
+55,184
+49% +$756K ﹤0.01% 2520
2022
Q2 		$1.02M Buy
113,195
+15,418
+16% +$105K ﹤0.01% 2789
2022
Q1 		$733K Hold
97,777
– – ﹤0.01% 2975
2021
Q4 		$839K Buy
97,777
+3,886
+4% +$33.8K ﹤0.01% 2971
2021
Q3 		$790K Sell
93,891
-60
-0.1% -$460 ﹤0.01% 2968
2021
Q2 		$762K Buy
+93,951
New +$794K ﹤0.01% 3022
2019
Q2 		– Sell
-9,548
Closed -$168K – 3228
2019
Q1 		$168K Hold
9,548
– – ﹤0.01% 3045
2018
Q4 		$169K Buy
+9,548
New +$283K ﹤0.01% 3039

Other funds holding COGT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Charles Schwab's COGT Position: Q2 2026 in Review

Charles Schwab increased its Cogent Biosciences (COGT) stake by 17% in Q2 2026, buying an estimated $7.24M and bringing the position to 1,449,300 shares worth $56.1M. The position accounts for 0.01% of the portfolio, ranked #1169.

Charles Schwab first reported a position in COGT in Q4 2018 and has held it in 23 quarters since. 323 funds tracked by Wall St. Rank hold COGT as of Q2 2026.

  • Charles Schwab held 1,449,300 shares of Cogent Biosciences worth $56.1M as of Q2 2026.
  • Charles Schwab bought 206,978 Cogent Biosciences shares in Q2 2026, an estimated $7.24M.
  • Cogent Biosciences made up 0.01% of Charles Schwab's portfolio in Q2 2026, its #1169 holding.
  • Charles Schwab first reported a position in Cogent Biosciences in Q4 2018 and has held it in 23 quarters since.
  • 323 funds tracked by Wall St. Rank held Cogent Biosciences as of Q2 2026.

Based on Charles Schwab's 13F filing for Q2 2026, filed 14 Aug 2026.